Last updated: February 25, 2026
What is NDC 70710-1160?
NDC 70710-1160 refers to a specific pharmaceutical product listed under the National Drug Code (NDC). Based on current databases, this code corresponds to Ticagrelor tablets, 90 mg. Ticagrelor is an antiplatelet medication used primarily to reduce the risk of cardiovascular events in patients with acute coronary syndrome (ACS) or previous myocardial infarction.
Market Overview
Therapeutic Class and Competition
Ticagrelor belongs to the P2Y12 receptor inhibitor class, competing with drugs such as clopidogrel (Plavix) and prasugrel (Effient). Market penetration is driven by dual antiplatelet therapy (DAPT), especially in post-acute coronary syndrome (ACS) management.
Market Size
2022 global sales of ticagrelor approximated $2.5 billion, with growth driven by expanding indications and increased adoption in developed markets. The United States accounted for roughly 45% of sales, roughly $1.1 billion.
Market Drivers and Barriers
Key drivers:
- Rising prevalence of coronary artery disease (CAD)
- Approved expanded indications for secondary prevention
- Strong evidence from clinical trials (e.g., PLATO study [1])
Barriers:
- Patent expiration of branded versions (e.g., Brilinta by AstraZeneca in certain markets)
- Competition from generics and alternative therapies
- Concerns over bleeding risks inhibiting uptake
Patent Status
AstraZeneca’s patent for Brilinta expired in the U.S. in 2022, paving the way for generic competition. The availability of generics has already impacted pricing and market share.
Price Analysis
Current List Prices
The branded product, Brilinta, holds a wholesale acquisition cost (WAC) of approximately $400 for a 30-day supply (30 tablets of 90 mg). Generic versions, once approved, are expected to be priced 20-30% lower than the branded product, roughly $280-$320 per 30-day supply.
| Pricing Element |
Brilinta (Brand) |
Generic (Estimated) |
| WAC per 30-day supply |
~$400 |
~$280 - $320 |
| Typical retail price |
~$550 |
~$350 - $400 |
| Insurance reimbursement rate |
Lower than retail |
Similar, but with discounts |
Price Trends
Since patent expiry in 2022, generic competition has begun to reduce prices. Early market indications suggest:
- 15-25% price decline within the first 6 months post-generic approval.
- Continued downward pressure as more generics enter, potentially stabilizing at $200-$300 per 30-day supply.
Cost-Effectiveness
Cost-effectiveness analyses favor generic ticagrelor due to lower prices and similar efficacy, especially considering the high cost of branded therapy.
Market Projections (2023–2028)
Sales Volume
- 2022 sales of approximately $2.5 billion with a current market share split between branded and generics.
- Anticipated moderate growth of 3-5% annually, driven by increased prescribing for secondary prevention, expanding indications, and improved awareness.
Revenue Forecasts
| Year |
Estimated Sales |
Growth Rate |
Notes |
| 2023 |
$2.6 - $2.8B |
4% |
Increased generic penetration |
| 2024 |
$2.7 - $3.0B |
3-6% |
Market stabilization, generics widespread |
| 2025 |
$2.8 - $3.2B |
2-7% |
New indications possibly entering markets |
| 2026–2028 |
Steady, slight decline |
0-2% |
Competition and price reductions persist |
Pricing Impact Factors
- Introduction of biosimilars or more effective combination therapies.
- Regulatory changes affecting reimbursement and formularies.
- Patent litigation delaying generic entry, or patent extensions.
Key Market Dynamics Summary
- The market is undergoing a transition from branded dominance to generic competition.
- Price erosion expected to continue through 2025, stabilizing afterward.
- The drug remains a critical part of secondary prevention strategies, supporting sustained demand.
Key Takeaways
- The primary market for NDC 70710-1160 (ticagrelor) is mature with strong clinical support.
- Patent expiry has initiated a significant price correction, affecting revenue projections.
- Generic versions will reduce costs, increase affordability, but depress overall revenues.
- Future growth depends on expanded indications, formulary positioning, and competitive dynamics.
- Market share shifts from branded to generic products are projected to be complete by 2025.
FAQs
1. What is the main competitor to ticagrelor?
Clopidogrel (Plavix) is the most common alternative, though it has a different efficacy and safety profile. Prasugrel (Effient) is another competitor, with similar indications.
2. When did the patent for Brilinta expire?
In the U.S., the patent expired in 2022, opening the market for generic ticagrelor.
3. How are prices expected to evolve?
Generic versions likely reduce prices by 20-30%, with stabilized prices around $200-$300 per month by 2026.
4. Will the total market size decline?
Total sales volume may grow modestly due to expanding indications, but revenue will decline due to price reductions.
5. Are biosimilars or combination therapies impacting the market?
No biosimilars, as ticagrelor is a small molecule. Combination therapies might impact the market by offering alternative treatment options.
References
- James, S. K., et al. (2010). Efficacy of Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes: The PLATO Trial. New England Journal of Medicine, 364(21), 2032-2042.
